Mizuho began coverage on shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) in a report published on Thursday. The brokerage issued a buy rating and a $82.00 target price on the medical research company’s stock.

Other analysts also recently issued research reports about the company. Zacks Investment Research raised PRA Health Sciences from a hold rating to a buy rating and set a $83.00 price target on the stock in a research note on Tuesday, August 15th. Jefferies Group LLC set a $73.00 price target on PRA Health Sciences and gave the company a buy rating in a research note on Thursday, June 1st. BidaskClub downgraded PRA Health Sciences from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Citigroup Inc. reissued a buy rating and issued a $90.00 price target (up previously from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. Finally, Bank of America Corporation initiated coverage on PRA Health Sciences in a research note on Monday, June 26th. They issued a buy rating and a $89.00 price target on the stock. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $84.22.

PRA Health Sciences (NASDAQ PRAH) traded down 0.82% on Thursday, reaching $75.06. The company had a trading volume of 282,122 shares. The firm has a 50 day moving average price of $75.71 and a 200-day moving average price of $70.59. PRA Health Sciences has a 12 month low of $50.87 and a 12 month high of $80.99. The stock has a market capitalization of $4.70 billion, a price-to-earnings ratio of 48.46 and a beta of 0.45.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.10). PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The business had revenue of $457.90 million for the quarter, compared to the consensus estimate of $447.79 million. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The business’s revenue was up .5% on a year-over-year basis. Analysts forecast that PRA Health Sciences will post $3.19 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “PRA Health Sciences, Inc. (PRAH) Coverage Initiated by Analysts at Mizuho” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/22/pra-health-sciences-inc-prah-coverage-initiated-by-analysts-at-mizuho.html.

In related news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $711,075,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Linda Baddour sold 100,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $7,485,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,000,000 shares of company stock worth $748,500,000. 2.10% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. First Bank & Trust increased its position in shares of PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock valued at $241,000 after acquiring an additional 52 shares during the last quarter. Renaissance Group LLC increased its position in shares of PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock valued at $393,000 after acquiring an additional 126 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of PRA Health Sciences by 0.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock valued at $1,428,000 after acquiring an additional 140 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 160 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in shares of PRA Health Sciences by 1.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock valued at $638,000 after acquiring an additional 160 shares during the last quarter. 98.37% of the stock is currently owned by institutional investors and hedge funds.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.